Edition:
United States

Becton Dickinson and Co (BDX.N)

BDX.N on New York Stock Exchange

166.51USD
9 Dec 2016
Change (% chg)

$2.87 (+1.75%)
Prev Close
$163.64
Open
$163.67
Day's High
$166.77
Day's Low
$163.67
Volume
199,720
Avg. Vol
274,808
52-wk High
$181.75
52-wk Low
$129.58

BDX.N

Chart for BDX.N

About

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical devices, instrument systems and reagents used by healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. The... (more)

Overall

Beta: 0.99
Market Cap(Mil.): $34,743.98
Shares Outstanding(Mil.): 212.32
Dividend: 0.73
Yield (%): 1.78

Financials

  BDX.N Industry Sector
P/E (TTM): 36.40 30.43 30.35
EPS (TTM): 4.50 -- --
ROI: 4.51 13.26 15.27
ROE: 13.18 17.03 16.60

Becton Dickinson wins reversal of $340 million syringe award

A federal appeals court on Friday threw out an antitrust verdict that ordered medical device maker Becton Dickinson and Co to pay rival Retractable Technologies Inc $340 million in damages over its marketing of safety syringes.

Dec 02 2016

BRIEF-Becton Dickinson board increases dividend

* Declared a quarterly dividend of $0.73 per common share, an increase of 10.6 percent from previous quarter Source text for Eikon: Further company coverage:

Nov 21 2016

BRIEF-Becton, Dickinson and Co announces tender offers for outstanding debt securities

* Becton, Dickinson and Company announces tender offers for outstanding debt securities

Nov 16 2016

BRIEF-Becton Dickinson launches syringe for use with Humulin R U-500 insulin

* BD launches first syringe designed for use with Humulin R U-500 insulin Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

Nov 08 2016

BRIEF-BD reports results for Q4 provides full-year fiscal 2017 guidance

* Becton Dickinson and Co - expects full fiscal year 2017 revenues to decrease 3.0 to 3.5 percent

Nov 03 2016

BRIEF-BD says Max Vaginal Panel receives FDA market authorization for test

* Bd max vaginal panel receives fda market authorization to detect most common causes of vaginal infections Source text for Eikon: Further company coverage:

Oct 31 2016

BRIEF-Becton Dickinson expects a material tax loss on Apax JV deal

* Becton Dickinson and Co expects to record a material tax loss on Apax JV deal at time of closing Source text for Eikon: Further company coverage: ;))

Oct 04 2016

BRIEF-Becton Dickinson invests $100 mln in Nebraska plant to expand insulin syringe manufacturing

* BD invests $100 million in Nebraska plant to expand insulin syringe manufacturing

Sep 22 2016

BRIEF-BD submits pre-market approval application to FDA for BD Onclarity HPV test

* Says intends to ultimately seek approval using HPV genotyping beyond 16, 18 and 45 Source text for Eikon: Further company coverage:

Sep 06 2016

BRIEF-Becton Dickinson names Andrew Eckert to board of directors

* Names Andrew Eckert to board of directors Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)

Jul 28 2016

Earnings vs. Estimates